Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Angers – page 10

681 clinical trials in Angers, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Angers at a glance
681
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

681 trials in Angers

Open in trial search

Renal transplant

Recruiting

Study of Belatacept versus Tacrolimus in Kidney Transplant Recipients with Subclinical Antibody Mediated Rejection

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Belatacept
  • Sponsor:Centre Hospitalier Universitaire Rouen

Non-small cell lung cancer

Recruiting

Study Comparing Tepotinib to Standard Treatment for Patients with Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Intergroupe Francophone De Cancerologie Thoracique

Haematological malignancy+1

Recruiting

Study on Fecal Microbiota Transplantation to Prevent Complications in Patients After Stem Cell Transplant for Blood Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Allogeneic Faecal Microbiota
  • Sponsor:CHU Gabriel-Montpied

Follicular lymphoma+7

Recruiting

Study on Safe Skin Test Concentrations for Biotherapy Allergies in Patients with Cancer Using Atezolizumab, Daratumumab, and Nivolumab

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Atezolizumab
  • Sponsor:Centre Hospitalier Universitaire D'Angers

Non-small cell lung cancer metastatic

Recruiting

Study of Adagrasib with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Idiopathic pulmonary fibrosis+1

Recruiting

Long-Term Safety Study of Inhaled Pirfenidone for Patients with Progressive or Idiopathic Pulmonary Fibrosis

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pirfenidone
  • Sponsor:Avalyn Pharma Inc.

Peripheral T-cell lymphoma unspecified+1

Recruiting

Study on Azacitidine, Roginolisib, and Golcadomide for Patients with Relapsed or Refractory Peripheral T-Cell Lymphomas

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:LYSARC

Non-small cell lung cancer

Recruiting

Study comparing NVL-655 to alectinib in untreated patients with ALK-positive advanced non-small cell lung cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:NVL-655
  • Sponsor:Nuvalent Inc.

Pancreatic carcinoma

Recruiting

Study on Chemotherapy for Patients with Resected Pancreatic Cancer Using FOLFIRINOX and Drug Combination

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Centre Hospitalier Universitaire Rouen

Adenocarcinoma pancreas

Recruiting

Study on Optimizing NALIRIFOX and 5-FU for Metastatic Pancreatic Cancer in First-Line Treatment and Exploring Ciprofloxacin in Second-Line Therapy

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ciprofloxacin
  • Sponsor:Association Gercor

Small cell lung cancer extensive stage

Recruiting

Study Comparing Sacituzumab Govitecan and Standard Treatment for Patients with Previously Treated Extensive Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan
  • Sponsor:Gilead Sciences Inc.

Blastic plasmacytoid dendritic cell neoplasia

Recruiting

Study on the Effectiveness and Safety of Tagraxofusp and Venetoclax for Adults with Untreated Blastic Plasmacytoid Dendritic Cell Neoplasm

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tagraxofusp
  • Sponsor:French Innovative Leukemia Organization (F.I.L.O.).

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Angers

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on multiple myeloma, breast cancer, and various forms of lung cancer. Studies are evaluating new combination therapies and treatment approaches for both early-stage and advanced cancers.

  • Triple-negative breast cancer treatments
  • Advanced non-small cell lung cancer therapies
  • Head and neck squamous cell carcinoma studies

Research includes investigation of novel drug combinations and immunotherapy approaches.

02 Cardiovascular Studies

Clinical research addressing heart failure prevention and acute myocardial infarction management. Studies are exploring innovative pain management approaches and preventive treatments.

  • Heart failure risk reduction
  • Pulmonary hypertension treatments
  • Emergency cardiac care interventions

Focus on both acute care solutions and long-term prevention strategies.

03 Immunology and Transplantation

Comprehensive research in kidney transplantation and immune disorders, including studies on preventing rejection and managing immunosuppression.

  • Transplant rejection prevention
  • Immune response monitoring
  • Novel immunotherapy approaches

Trials aim to improve long-term outcomes for transplant recipients and immune disorder patients.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.